Alterity Therapeutics Ltd (ASX:ATH) Share Price Update: Trading Snapshot for 11 August 2026

Anjali Anand

11 August 2026 11:13 PM AEST

Alterity Therapeutics Ltd (ASX:ATH) Share Price Update: Trading Snapshot for 11 August 2026

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Alterity Therapeutics Ltd (ASX:ATH) recorded a change of 0.94% in its share price on 11 August 2026.
The stock traded within an intraday range during the session, with Volume of 13,665 shares changing hands.
Market capitalisation was recorded at $117.6M as at close on the day.
The S&P/ASX 200 Health Care index closed higher, up 2.15% for the session.
Alterity Therapeutics Ltd operates within the neurodegenerative disease research and biotechnology segment of the health care sector.

Alterity Therapeutics Ltd, listed on the Australian Securities Exchange under the code ATH, was among the health care sector stocks that recorded trading activity on 11 August 2026. This article provides an educational overview of the company's most recent trading data, alongside general context on the S&P/ASX 200 Health Care index, of which the sector forms a part. The information below is intended to help readers understand publicly available market data and should not be read as commentary on the merits of the company or its shares.

ATH Share Price Movement on 11 August 2026

On 11 August 2026, shares of Alterity Therapeutics Ltd were recorded at a closing price of $0.54, reflecting a change of 0.94% for the session. During the day, the stock moved between an intraday low of $0.535 and an intraday high of $0.545. Trading volume for the session stood at 13,665 shares, a figure that reflects the level of trading interest recorded on the day. Market capitalisation, which represents the total value of the company's listed shares at the given price, was recorded at $117.6M. These figures are drawn directly from end-of-day market data as at close on 11 August 2026 (AEST) and are presented for informational purposes only.

About Alterity Therapeutics Ltd

Alterity Therapeutics Ltd is a clinical-stage biotechnology company associated with research into treatments for neurodegenerative conditions, including disorders connected to abnormal movement and cognition. Clinical-stage biotechnology companies of this nature are generally linked to trial timelines and research updates, which can be a Factor in how their shares trade over time.

Health Care Sector Context: S&P/ASX 200 Health Care Index

Alterity Therapeutics Ltd is classified within the health care sector of the Australian share market, which is tracked through the S&P/ASX 200 Health Care index (ticker: XHJ). On 11 August 2026, the index closed at 28,991.5 points, a change of 610.6 points, or 2.15%, compared with the previous close of 28,380.9. During the session, the index traded within a range of 28,380.9 to 29,037.6. Over the preceding 52 weeks, the index has traded between 21,947.2 and 45,579.6, and it recorded a one-year return of -34.57%. As a constituent of this sector grouping, Alterity Therapeutics Ltd's trading activity can generally be viewed alongside broader movements recorded across the neurodegenerative disease research and biotechnology segment of the market.

One-Year Performance Snapshot

Looking at a longer time frame, Alterity Therapeutics Ltd recorded a one-year return of -22.86% as at 11 August 2026. This figure reflects the change in share price over the preceding twelve months and is one of several data points that may be reviewed alongside Market Capitalisation and trading volume when looking at historical patterns. Past price movements are historical in nature and do not indicate how a share price may behave in the future.

Conclusion

In summary, Alterity Therapeutics Ltd (ASX:ATH) was among the health care sector companies that saw share price movement during trading on 11 August 2026, against a backdrop of a positive session for the broader S&P/ASX 200 Health Care index. Reviewing figures such as daily price change, trading volume, market capitalisation and one-year returns can help readers build a general understanding of how a listed company's shares have traded over time. Readers may wish to refer to official market data sources and company disclosures for the most current information. This article is intended for general educational purposes only and does not constitute financial advice, a recommendation, or a valuation of any security.

FAQs

Q: What is the ASX ticker code for Alterity Therapeutics Ltd?

A: Alterity Therapeutics Ltd is listed on the Australian Securities Exchange under the code ATH.

Q: What was the share price movement for ATH on 11 August 2026?

A: Shares of Alterity Therapeutics Ltd recorded a change of 0.94% during the trading session on 11 August 2026, closing at $0.54.

Q: Which sector does Alterity Therapeutics Ltd belong to?

A: Alterity Therapeutics Ltd is part of the health care sector and is a constituent of the S&P/ASX 200 Health Care index (XHJ).

Q: How did the S&P/ASX 200 Health Care index perform on 11 August 2026?

A: The index closed at 28,991.5 points, up 610.6 points, or 2.15%, compared with the previous close.

Q: Does this article provide investment advice regarding Alterity Therapeutics Ltd?

A: No. This article is for general educational purposes only and does not provide financial advice, valuation, or a recommendation to buy or sell any security.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.